File No: BIO/CT/22/000003

Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licencing Authority hereby permits Dr. Manoj Murhekar of M/s National Institute Of Epidemiology, Indian Council Of Medical Research, R127, 2nd Main Road, Tamil Nadu Housing Board(TNHB) Ayapakkam, Chennai-600077, Chennai (India) – 600077, Telephone No.: 044-26136201, FAX: 044-26820464 E-Mail : mmurhekar@gmail.com, to conduct clinical trial of the new drug or investigational new drug as per Protocol No.: NIE/IHEC/202112-01 in the below mentioned clinical trial sites.

CT No.:	**CT- 03/2022**

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

4. It may kindly be noted that merely granting permission to conduct Clinical trial with the vaccine does not convey or imply that, based on the Clinical trial data generated with the vaccine, permission to market this vaccine in the country will automatically be granted to you.

VENUGOPAL G SOMANI

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA), pseudonym=112046a34e21727bacb255748732c456d249073e55e953d9cb5b58748ee3113c, postalCode=110002, st=DELHI, serialNumber=e97f241aa0c0bba41522525ffca0705074b4997e6b2f4b5c8d81cf282adeaf5d, cn=VENUGOPAL G SOMANI
Date: 2022.03.08 17:56:52 +05'30'

Place: New Delhi
Date: 08-March-2022

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority
Stamp

Annexure:

Details of New Drug or Investigational New Drug:

<table>
<tr><td colspan="2">COVAXIN vaccine:</td></tr>
<tr><td>Name of the new drug or investigational new drug:</td><td>Whole Virion Inactivated Corona Virus Vaccine</td></tr>
<tr><td>Therapeutic class:</td><td>Vaccine</td></tr>
<tr><td>Dosage form:</td><td>Suspension for injection
Route of Administration: Intramuscular</td></tr>
<tr><td>Composition:</td><td>Each dose of 0.5ml of vaccine contains:
<table>
<tr><th>Active Ingredients</th><th>Quantity</th></tr>
<tr><td>Whole Virion, Inactivated Corona Virus antigen (Strain: NIV-2020-770)</td><td>6 mcg</td></tr>
<tr><th>Inactive Ingredients</th><th>Quantity</th></tr>
<tr><td>Aluminium Hydroxide gel equivalent to Al^{+++}</td><td>250 mcg</td></tr>
<tr><td>TLR 7/8 Agonist</td><td>15 mcg</td></tr>
<tr><td>2-Phenoxyethanol (2PE) I.P.</td><td>2.5 mg</td></tr>
<tr><td>Phosphate Buffered Saline</td><td>q.s. to 0.5 mL</td></tr>
</table>
* Produced in Vero cells.</td></tr>
<tr><td>Indications:</td><td>For active immunization against Corona Virus Disease (COVID-19) for age ≥18 years when administered in two doses interval of day 0 & day 28.</td></tr>
<tr><td colspan="2">COVISHIELD vaccine:</td></tr>
<tr><td>Name of the new drug or investigational new drug:</td><td>ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)</td></tr>
<tr><td>Therapeutic class:</td><td>Vaccine</td></tr>
<tr><td>Dosage form:</td><td>Solution for injection
Route of Administration: Intramuscular</td></tr>
<tr><td>Composition:</td><td>Each dose of 0.5ml of vaccine contains:
<table>
<tr><th>Active Ingredients</th><th>Quantity</th></tr>
<tr><td>Replication- deficient chimpanzee adeno virus particles encoding SARS-CoV-2 spike (S) glycoprotein*</td><td>5×10^{10} virus particles</td></tr>
<tr><th>Inactive Ingredients</th><th>Quantity</th></tr>
<tr><td>L-Histidine and L-Histidine Hydrochloride</td><td>10 mM</td></tr>
<tr><td>Sodium Chloride</td><td>35 mM</td></tr>
<tr><td>Magnesium Chloride</td><td>1 mM</td></tr>
<tr><td>Polysorbate 80</td><td>0.1% (w/v)</td></tr>
<tr><td>Sucrose</td><td>7.5% (w/v)</td></tr>
<tr><td>Ethanol</td><td>0.5% (w/v)</td></tr>
<tr><td>EDTA Disodium Salt</td><td>0.1 mM</td></tr>
<tr><td>Water for Injection</td><td>q.s. to 0.5 ml</td></tr>
</table>
* Produced in genetically human embryonic kidney (HEK) 293 cells.</td></tr>
<tr><td>Indications:</td><td>For active immunization of individuals of ≥18 years old for the prevention of corona virus disease (COVID-19) when administered in two doses schedule. The second dose should be administered between 4 to 6 weeks after the first dose. However, there is data available for administration of the second dose up to 12 weeks after the first dose from the overseas studies.</td></tr>
</table>

Details of clinical trial sites-

S. No.	Name and Address of Clinical Trial Site	Ethics Committee details	Name of Principal Investigator
1	ICMR-National Institute of Epidemiology (NIE), Chennai	Institute of Ethics Committee, ICMR-National Institute of Epidemiology (NIE), Chennai [ECR/13R/INST/TN/2013.]	Dr. Manoj Murhekar
2	Cancer Institute (WIA)-Adyar, Chennai	Institute of Ethics Committee, Cancer Institute (WIA)-Adyar, Chennai [ECR/235/INST/TN/2013]	Dr. Venkatraman Radhakrishnan
3	Madras Medical College and Government General Hospital, Chennai, Rajiv Gandhi Government General Hospital, Poonamallee High Rd, Park Town, Chennai, Tamil Nadu.	Institute of Ethics Committee, Madras Medical College and Government General Hospital, Chennai, Rajiv Gandhi Government General Hospital, Poonamallee High Rd, Park Town, Chennai, Tamil Nadu 60000 [ECR/270/INST/TN/2013/RR-16]	Dr. Natarajan Gopalakrishnan
4	Government Hospital of Thoracic Medicine, Chennai.	Institute of Ethics Committee, Government Hospital of Thoracic Medicine, Chennai, [ECR/1547/INST/TN/2021]	Dr.Sridhar Rathinam
5	Tata Memorial Hospital, Mumbai	Institute of Ethics Committee, Tata Memorial Hospital, Mumbai, ECR/414/INST/MH/2013 6. Dr.Gita Nataraj, King Edward (VII) Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai [ECR/417/INST/MH/2013]	Dr. Manju Sengar
6	King Edward (VII) Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai.	Institute of Ethics Committee, King Edward (VII) Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai [ECR/417/INST/MH/201]	Dr.Gita Nataraj
7	Nair Hospital, Mumbai	Institute of Ethics Committee, Nair Hospital, Mumbai [ECR/22/INST/MH/2013/RR-19]	Dr. Jayanthi Shastri
8	Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry	Institute of Ethics Committee, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry [ECR/342/INST/PY/2013]	Dr Prasanth Ganesan
9	National Institute of Virology, Pune	Institute of Ethics Committee, National Institute of Virology [ECR/117/INST/MH/2013]	Dr Pragya Yadav
10	ICMR-National Institute for Research in Reproductive Health, Mumbai.	Institute of Ethics Committee, ICMR-National Institute for Research in Reproductive Health, Mumbai. [ECR/221/INST/MH/2013/RR-19]	Dr Vainav Patel

In addition to point 4, the permission is subject to following condition(s):

I. The Phase IV clinical trial should be conducted as per protocol titled “Safety and immunogenicity of the third dose of COVISHIELD/COVAXIN vaccine using homologous and heterologous regimen in immunocompromised patients: Single-blind, Randomized, non-inferiority” vide Protocol No: NIE/IHEC/202112-01.

II. Firm is required to submit the following documents/information:

a. Revised clinical trial protocol as per the recommendations of SEC (COVID-19) meeting dated 31.01.2022.
b. Duly signed copy of the Investigator's Brochure for the proposed clinical trial.
c. Duly filled and signed copy of contract entered by the sponsor with the investigator/institutions with regard to financial support, amount of fees, honorarium, and payments in kind etc. to be paid to the investigator.
d. Copy of Insurance certificate for the proposed Phase IV trial.

III. The firm is required to constitute a DSMB to review the safety data.

IV. The formulation intended to be used in the clinical trial shall be manufactured using validated procedures under GMP conditions and shall have ongoing stability programme

V. Only CDL, Kasauli certified batches shall be used in the clinical trial.

VENUGOPAL G SOMANI

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA), pseudonym=112046a34e21727bacb255748732c456d249073e55e953d9cb5b58748ee3113c, postalCode=110002, st=DELHI, serialNumber=e97f241aa0c0bba41522525ffca0705074b4997e6b2f4b5c8d81cf282adeaf5d, cn=VENUGOPAL G SOMANI
Date: 2022.03.08 17:57:01 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority

Place: New Delhi
Date: 08-March-2022

Stamp

CENTRAL DRUGS STANDARD CONTROL ORGANIZATION
CDSCO
सत्यमेव जयते
MINISTRY OF HEALTH, GOVERNMENT OF INDIA